Abstract: A battery bank control device is provided for setting a power limit value of a battery bank in which a plurality of battery racks (BRs) are connected in parallel. The device includes: a voltage measurement unit measuring a voltage of each BR of the plurality of BRs; a first power limit calculation unit calculating a first power limit value according to a state of charge (SOC) calculated based on the voltage of each BR with respect to each BR; a capacity ratio calculation unit calculating a capacity ratio of each BR based on capacity information of the plurality of BRs; a second power limit calculation unit calculating a second power limit value using the capacity ratio and the first power limit value of each BR; and a battery bank power limit calculation unit calculating a battery bank power limit value using the second power limit value of each BR.

Abstract: A battery diagnosis apparatus for diagnosing a battery including battery cells, the apparatus according to an embodiment may include a voltage measurer for measuring the voltage of each battery cell during a preset period of time, a voltage variation calculator for calculating an individual voltage variation of each battery cell during the preset period of time, an average voltage variation calculator for calculating an average voltage variation of the battery cells during the preset period of time, and an abnormality detector for determining that a voltage abnormality has occurred in at least one battery cell among the battery cells when a difference between the voltage variation of the at least one battery cell and the average voltage variation of the at least one battery cell is greater than a threshold value.

Abstract: The invention concerns human thrombopoietin and in particular modified forms of thrombopoietin (TPO) with improved properties. The improved proteins contain amino acid substitutions at specific positions within the TPO molecule. The invention provides modified TPO molecules, preferably fusion proteins comprising immunoglobulin constant regions and modified human TPO, with improved biological activity concomitant with reduced immunogenic potential in the protein. The improved proteins are intended for therapeutic use in the treatment of diseases in humans.